Identification
- Generic Name
- Interferon Kappa
- DrugBank Accession Number
- DB15749
- Background
Interferon kappa is a subclass of type I interferon mediating host defence which consists of 207 amino acids and has 30% homology with others of the same class as it consists of a series of cysteine and a 27-amino acid signal peptide conserved in type I interferons. This gene encoding for this interferon is expressed in human epidermal keratinocytes.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Interferons - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- IFN‐κ
- External IDs
- Interferon Kappa
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Significant interferon kappa expression enhancement occurs with: viral infection, exposure to double-stranded RNA, or treatment with interferon gamma or interferon beta. It was also found cellular protection against viral infection occurs in a species-specific manner. The mechanism by which IFN-κ acts involves the activation of the interferon-stimulated response element signalling pathway and a panel of genes which include anti-viral mediators and transcriptional regulators, similar to those regulated by other type I interferons. Also as with other type I interferons, IFN-κ binds at the same receptors, which are interferon-α/β receptor 1(IFNAR1) and IFNAR2.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAminophylline The metabolism of Aminophylline can be decreased when combined with Interferon Kappa. Bromotheophylline The metabolism of Bromotheophylline can be decreased when combined with Interferon Kappa. Caffeine The metabolism of Caffeine can be decreased when combined with Interferon Kappa. Dyphylline The metabolism of Dyphylline can be decreased when combined with Interferon Kappa. Lomifylline The metabolism of Lomifylline can be decreased when combined with Interferon Kappa. - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
References
- General References
- LaFleur DW, Nardelli B, Tsareva T, Mather D, Feng P, Semenuk M, Taylor K, Buergin M, Chinchilla D, Roshke V, Chen G, Ruben SM, Pitha PM, Coleman TA, Moore PA: Interferon-kappa, a novel type I interferon expressed in human keratinocytes. J Biol Chem. 2001 Oct 26;276(43):39765-71. doi: 10.1074/jbc.M102502200. Epub 2001 Aug 20. [Article]
- de Weerd NA, Nguyen T: The interferons and their receptors--distribution and regulation. Immunol Cell Biol. 2012 May;90(5):483-91. doi: 10.1038/icb.2012.9. Epub 2012 Mar 13. [Article]
- External Links
- Not Available
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at August 11, 2020 21:55 / Updated at August 13, 2020 07:02